Magnesium Supplementation for the Prevention of Cisplatin-Induced Nephrotoxicity

This prospective, randomized, open-label study evaluated whether intravenous magnesium sulphate added to standard hydration could reduce cisplatin-associated renal toxicity in adult patients with solid tumors receiving weekly cisplatin-based chemoradiotherapy. Participants were assigned to standard hydration with intravenous saline and furosemide or to the same hydration protocol supplemented with 1 g of intravenous magnesium sulphate before cisplatin administration. The primary outcome was early renal toxicity assessed 48 hours after cisplatin administration. Secondary outcomes included renal dysfunction at one year, changes in urinary kidney injury biomarkers (KIM-1, NGAL, and suPAR), hematological toxicity, and treatment response